A5050653034- Autoimmune Bullous Skin Diseases
- Urticaria and Related Conditions
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Drug-Induced Adverse Reactions
- Platelet Disorders and Treatments
- Nail Diseases and Treatments
- Dermatological and Skeletal Disorders
- Eosinophilic Disorders and Syndromes
- Cutaneous lymphoproliferative disorders research
- Oral and gingival health research
- Histiocytic Disorders and Treatments
- Autoimmune and Inflammatory Disorders
- Chronic Lymphocytic Leukemia Research
- Immunodeficiency and Autoimmune Disorders
- Skin Diseases and Diabetes
- Hair Growth and Disorders
- SARS-CoV-2 and COVID-19 Research
- Dermatological and COVID-19 studies
- Sympathectomy and Hyperhidrosis Treatments
- Cutaneous Melanoma Detection and Management
- Plant Pathogens and Fungal Diseases
- Psoriasis: Treatment and Pathogenesis
- Blood disorders and treatments
- Immunotherapy and Immune Responses
- Intramuscular injections and effects
Centre Hospitalier Universitaire de Lille
2017-2025
Lille’s Cardiology Hospital
2016-2025
Université de Lille
2018-2025
Hôpital Claude Huriez
2017-2023
Centre Hospitalier de Vitré
2017-2023
Université de Rouen Normandie
2012-2021
Inserm
2012-2021
Normandie Université
2020-2021
Hopitaux Civils de Colmar
2021
Duke Medical Center
2021
Importance Rituximab is approved for the treatment of moderate to severe pemphigus. However, 20% patients in RITUX 3 trial relapsed within first year treatment. Objective To assess outcome an additional rituximab infusion at month 6 with pemphigus who were complete remission (CR) after regimen but had 1 or more predictors relapse 3. Design, Settings, and Participants This multicenter cohort study was conducted France from September 2018 June 2023 newly diagnosed CR Relapse factors a...
<h3>Importance</h3>A rare variant of mucous membrane pemphigoid (MMP) is characterized by circulating anti–laminin 332 (Lam332) autoantibodies and seems to be associated with concurrent malignant neoplasms.<h3>Objective</h3>To determine the prevalence clinical significance anti-Lam332 autoantibody detection from a large series patients MMP.<h3>Design</h3>Multicenter retrospective study.<h3>Setting</h3>Four French national centers for autoimmune bullous diseases.<h3>Participants</h3>One...
Corticosteroids (CS) with or without adjuvant immunosuppressant agents are standard treatment for pemphigus vulgaris (PV). The efficacy of therapies in minimizing steroid‐related adverse events (AEs) is unproven. To utilize data collected a French investigator‐initiated, phase III, open‐label, randomized controlled trial to demonstrate the and safety rituximab seek approval its use PV. This was an independently conducted post hoc analysis moderate‐to‐severe PV subset enrolled Ritux 3 study....
Aims Linear immunoglobin A (IgA) bullous dermatosis is a rare autoimmune considered spontaneous or drug‐induced (DILAD). We assessed all DILAD cases, determined the imputability score of drugs and highlighted suspected drugs. Methods Data for patients with were collected retrospectively from French Pharmacovigilance network (from 1985 to 2017) physicians involved in Bullous Diseases Study Group Investigators Skin Adverse Reactions Drugs. Drug causality was systematically by method. Results...
Rituximab and short-term corticosteroid therapy are the criterion standard treatments for patients with newly diagnosed moderate to severe pemphigus.To examine factors associated relapse in pemphigus treated rituximab.This post hoc analysis of a randomized clinical trial (Comparison Between Treatment Oral Corticosteroid Patients With Pemphigus [RITUX 3]) conducted from January 1, 2010, December 31, 2015, included 20 dermatology departments tertiary care centers France RITUX 3 according...
Abstract Background Interest in the use of omalizumab to treat bullous pemphigoid (BP) event resistance or contraindication conventional therapies is currently based on limited evidence. Objectives To assess effectiveness and safety BP identify predictive factors response treatment. Methods We conducted a French national multicentre retrospective study including patients with confirmed diagnosis treated after failure one several treatment lines. excluded clinically atypical BP, as per...
Importance The Ritux 3 trial demonstrated the short-term efficacy and safety of first-line treatment with rituximab compared a standard corticosteroid regimen in pemphigus. No data on long-term follow-up patients who received as first line are available. Objective To assess regimen. Design, Setting, Participants This 7-year study included pemphigus from 25 dermatology departments France January 1, 2010, to December 31, 2015. Exposure Patients were initially randomized plus prednisone group...
Background The Bullous Pemphigoid Disease Area Index (BPDAI) score has been proposed to provide an objective measure of bullous pemphigoid (BP) activity. Objectives this study was calculate BPDAI cut-off values defining mild, moderate and severe BP. We also aimed assess the interrater reliability correlation with number daily new blisters, anti-BP180 anti-BP230 antibodies. Methods Severity scores were recorded by two blinded investigators. Anti-BP180 antibodies measured using enzyme-linked...
Anti‐p200 pemphigoid is a rare autoimmune blistering disease (AIBD) of the dermoepidermal junction, characterized by autoantibodies to laminin γ1. The clinical course anti‐p200 in patients remains poorly investigated. We aimed describe and immunological features series with pemphigoid. conducted retrospective study immunoblotting detection sera on 200‐kDa dermal protein extracts from register French reference centre for AIBD. recorded patients. A total 14 mean age 81·6 ± 6·5 years were...
This cohort study examines the safety and efficacy of rituximab for patients with pempigus foliaceus.
Adverse pregnancy outcomes (APO) occur in 35% of patients with pemphigoid gestationis (PG). No biological predictor APO has been established yet.To assess a potential relationship between the occurrence and serum value anti-BP180 antibodies at time PG diagnosis.Multicentre retrospective study conducted from January 2009 to December 2019 35 secondary tertiary care centres.(i) diagnosis according clinical, histological immunological criteria, (ii) ELISA measurement IgG determined same...
Abstract Background The somatic BRAF V600E mutation occurs in 38–64% of pediatric cases Langerhans cell histiocytosis (LCH). Vemurafenib (VMF), a inhibitor, was approved for refractory mutated LCH. In adults, VMF causes frequent cutaneous adverse events (CAE) including skin tumors (squamous carcinomas, melanomas), but little is known children. objective this study to evaluate the frequency, clinical spectrum, and severity CAEs children treated with addition, correlation between CAE...
Linear IgA bullous dermatosis (LABD) is an autoimmune blistering skin disorder characterized by linear deposits along the dermoepidermal junction. Usually idiopathic, LABD can be drug-induced.To report atypical characteristics of a case trimethoprim-sulfamethoxazole-induced presenting as toxic epidermal necrolysis (TEN).A 63-year-old woman treated with trimethoprim-sulfamethoxazole for Pneumocystis jirovecii infection developed generalized maculopapular rash herpetiform lesions, rosette-like...